HNRNPR-mediated UPF3B mRNA Splicing Drives Hepatocellular Carcinoma Metastasis

Medicine, Hepatobiliary System, Oncology,
hepatocellular carcinoma   metastasis   splice variant   HNRNPR   UPF3B-S  

HNRNPR-Mediated UPF3B mRNA Splicing Drives Hepatocellular Carcinoma Metastasis In recent years, hepatocellular carcinoma (HCC) has become one of the leading causes of cancer-related deaths worldwide due to its highly invasive and metastatic nature. The mechanisms underlying HCC metastasis are complex, with abnormal alternative splicing (AS) playing...

Fibroblast Activation Protein-Targeted NIR-I/II Fluorescence Imaging for Detecting Hepatocellular Carcinoma

Medicine, Medical Imaging, Oncology, Life Sciences, Biochemistry,
hepatocellular carcinoma   cancer-associated fibroblasts   fibroblast activation protein   near-infrared fluorescence   peptide-targeted fluorescence imaging  

A Novel Near-Infrared Fluorescence Imaging Study Targeting Hepatocellular Carcinoma (HCC) Hepatocellular carcinoma (HCC) ranks as the sixth most common malignancy and the third leading cause of cancer-related mortality worldwide. Statistics indicate that the postoperative recurrence rate of HCC reaches as high as 80%, with liver fibrosis or cirrhos...

Hepatic Arterial Infusion Chemotherapy-Based Conversion Hepatectomy in Responders Versus Nonresponders with Hepatocellular Carcinoma: A Multicenter Cohort Study

Medicine, Hepatobiliary System, Oncology,
conversion hepatectomy   hepatic arterial infusion chemotherapy   hepatocellular carcinoma   tumor response   survival rate   surgical timing   multicenter study  

Hepatic Arterial Infusion Chemotherapy (HAIC)-Based Conversion Hepatectomy in Patients with Hepatocellular Carcinoma Academic Background Hepatocellular carcinoma (HCC) is one of the most common liver malignancies worldwide, particularly in China, where its incidence and mortality rates remain high. Despite advancements in treatment strategies, radi...

Evaluation of Treatment Outcomes Using DNLR and GNRI in Combination Therapy with Atezolizumab and Bevacizumab for Hepatocellular Carcinoma

Medicine, Hepatobiliary System, Oncology,
hepatocellular carcinoma   DNLR   GNRI   atezolizumab   bevacizumab   prognosis   immune checkpoint inhibitor  

Evaluation of Treatment Outcomes Using DNLR and GNRI in Combination Therapy for Hepatocellular Carcinoma Background Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide, particularly in Asia. Due to its lack of early symptoms, many patients are diagnosed at an advanced stage, making surgical resection unfeasible. In r...

Targeting SRSF10 Might Inhibit M2 Macrophage Polarization and Potentiate Anti-PD-1 Therapy in Hepatocellular Carcinoma

Medicine, Hepatobiliary System, Oncology, Life Sciences, Immunology,
hepatocellular carcinoma   immune checkpoint blockade   SRSF10   lactate metabolism   M2 macrophage polarization   tumor microenvironment   glycolysis  

The Role of SRSF10 in Immunotherapy for Hepatocellular Carcinoma Academic Background Hepatocellular carcinoma (HCC) ranks sixth in global cancer incidence and third in mortality. Although surgical resection is the primary treatment for HCC, the high postoperative recurrence rate significantly impacts patient prognosis. In recent years, immunotherap...

Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells

Medicine, Hepatobiliary System, Oncology, Life Sciences, Cell Biology, Biochemistry, Bioengineering, Immunology, Genetics,
TGF-β   signaling pathway   NK cells   hepatocellular carcinoma   iPSC   anti-tumor   immunotherapy  

Background Introduction Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, with a five-year survival rate of less than 20%, and treatment options are extremely limited. Traditional targeted drug therapies, such as Sorafenib and other kinase inhibitors, have been used to treat HCC, but their efficacy is limited and diffi...

Lipid Droplet Accumulation Mediates Macrophage Survival and Treg Recruitment via the CCL20/CCR6 Axis in Human Hepatocellular Carcinoma

Medicine, Rheumatology and Immunology, Hepatobiliary System, Basic Medical Sciences, Oncology, Life Sciences, Biochemistry, Immunology,
lipid droplets   macrophage survival   CCL20   Treg   hepatocellular carcinoma  

Lipid Droplet Accumulation Mediates Macrophage Survival and Treg Recruitment in Human Hepatocellular Carcinoma via the CCL20/CCR6 Axis Background Macrophages are a major component of the tumor microenvironment (TME) and regulate the entire tumor process. In the TME, macrophages exhibit dynamic heterogeneity and plasticity, which affects their role ...

A Novel Stratification Scheme Combined with Internal Arteries in CT Imaging for Guiding Postoperative Adjuvant Transarterial Chemoembolization in Hepatocellular Carcinoma: A Retrospective Cohort Study

Medicine, Hepatobiliary System, Medical Imaging, Oncology,
CT imaging   hepatectomy   hepatocellular carcinoma   prognosis   transarterial chemoembolization  

Retrospective Cohort Study on Innovative Stratification Scheme Based on Postoperative Combined CT Imaging to Guide Postoperative Adjuvant Transarterial Chemoembolization for Hepatocellular Carcinoma Background Hepatocellular carcinoma (HCC) is the sixth most common cancer globally and the fourth leading cause of cancer-related deaths. For HCC, live...

Watch-and-Wait Strategy vs. Resection in Patients with Radiologic Complete Response After Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma: A Propensity Score-Matching Comparative Study

Medicine, Hepatobiliary System, Gastroenterology, Oncology,
complete response   conversion therapy   hepatocellular carcinoma   surgical resection   watch-and-wait strategy  

Observation vs Surgical Resection for Initial Unresectable Hepatocellular Carcinoma after Conversion Therapy Background Hepatocellular carcinoma (HCC) is the sixth most common cancer globally and the third leading cause of cancer-related mortality. Partial hepatectomy can provide a 5-year survival rate of 70-80% in the treatment of early-stage HCC....